Bo Zhou

发表

Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts

Jianghua Chen, Ya-jun Guo, L. Du, 2010, mAbs.

Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects

Ya-jun Guo, Hao Wang, Wei-zhu Qian, 2012, mAbs.

Synergistic antitumor effect of the anti-ErbB2 antibodies trastuzumab and H2-18 on trastuzumab-resistant gastric cancer cells

Bo-hua Li, Bei-bei Liang, Y. Meng, 2021, Oncology letters.

Tolerability, pharmacokinetics and pharmacodynamics of CMAB001, an anti-CD11a antibody, in Chinese healthy volunteers and psoriatic patients

Hao Wang, Ya-jun Guo, Wei-zhu Qian, 2012, Acta Pharmacologica Sinica.

Two doses of humanized anti-CD25 antibody in renal transplantation

Ya-jun Guo, Wei-zhu Qian, T. Zhu, 2009, mAbs.

Targeting EGFR/HER2 heterodimerization with a novel anti‐HER2 domain II/III antibody

Shi Hu, Huajing Wang, Bo-hua Li, 2017, Molecular immunology.

Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit

Yue-qiang Fu, Cheng-jun Liu, Bo Zhou, 2022, Frontiers in Pediatrics.

Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors

Ya-jun Guo, Yuankai Shi, Wei-zhu Qian, 2011, mAbs.